Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Buy” by Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $12.14.

Several brokerages recently weighed in on STRO. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 target price on shares of Sutro Biopharma in a report on Friday, October 11th. Finally, Truist Financial dropped their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th.

Sutro Biopharma Stock Performance

STRO opened at $2.84 on Thursday. The stock has a market cap of $234.18 million, a price-to-earnings ratio of -1.76 and a beta of 1.09. The firm’s fifty day moving average is $3.40 and its 200 day moving average is $3.70. Sutro Biopharma has a fifty-two week low of $2.45 and a fifty-two week high of $6.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Gladius Capital Management LP bought a new position in shares of Sutro Biopharma during the 3rd quarter valued at about $28,000. ProShare Advisors LLC raised its position in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after buying an additional 5,373 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Sutro Biopharma during the 3rd quarter valued at about $77,000. Intech Investment Management LLC purchased a new stake in shares of Sutro Biopharma during the 3rd quarter valued at about $91,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at about $92,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.